Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …

Introduction Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting
from second-line treatment has led to an improvement in overall survival in locally advanced …

Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response
(pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC) …

B cells constitute a major component of infiltrating immune cells in colorectal cancer (CRC).
However, the characteristics of B cells and their clinical significance remain unclear. In this …

Cancer is the leading cause of death worldwide. Cancer immunotherapy involves
reinvigorating the patient's own immune system to fight against cancer. While novel …

Importance Although the combination of nivolumab plus ipilimumab has unquestionable
benefit over nivolumab monotherapy in advanced melanoma, currently no summative …

Opinion Statement There is an acute unmet need to develop novel treatment regimens in the
perioperative setting since many patients with muscle-invasive bladder cancer (MIBC) are …

Importance Melanoma treatment has evolved during the past decade with the adoption of
adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on …

As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major
unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue …

There have been significant advances in the treatment of urology cancers, with a number of
practice‐changing treatments. There is now greater clarity on the role of the use of …